COMMUNIQUÉS West-GlobeNewswire
-
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
13/10/2026 -
Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026
13/10/2026 -
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
13/10/2026 -
MediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to Panama
13/10/2026 -
Reflect Scientific Introduces PF-90 Blast Plate Freezer, Combining Two Freezing Technologies for Biopharmaceutical and Cell Therapy Applications
13/10/2026 -
Alignment Health Expands Medicare Advantage Coverage to Four New Charlotte-Area Counties for 2027
13/10/2026 -
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
13/10/2026 -
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
13/10/2026 -
Gala Reale di Savoia to make It’s Montreal debut in support of Point d’Appui Foundation
13/10/2026 -
Le Gala Reale Di Savoia fera ses débuts à Montréal au profit de la Fondation Point d’Appui
13/10/2026 -
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
13/10/2026 -
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
13/10/2026 -
Travelan® Phase 2 Study Results Published
13/10/2026 -
Transactions in connection with share buy-back program
13/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
13/10/2026 -
Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update
13/10/2026
Pages